A SAS sergeant testifying for Fairfax Media in the Ben Roberts-Smith’s defamation trial has admitted he told an investigative reporter the decorated veteran machine-gunned a disabled man during the war in Afghanistan, but insisted everything he said was true.
AMP has expressed optimism that it will be able to reach a settlement with DST Bluedoor in a $35.5 million lawsuit accusing it of poaching 11 DST employees after licensing the software company’s online platform.
A former circus performer has won the right to bring historical sexual harassment and victimisation claims against Circus Oz and its chairman Nick Yates.
Law firm Maddocks has bolstered its corporate practice with the addition of two senior mergers and acquisitions specialists, nabbed from Lander & Rogers and Herbert Smith Freehills.
As parliament weighs the latest Morrison government crackdown on class actions, the Federal Court’s chief judge has warned of “an ever present danger” of maligning the regime.
Bristol-Myers Squibb has agreed to open up its subsidised treatment program for stage IV melanoma patients to individuals who have been treated with drugs made by its competitors to settle a misuse of market power lawsuit brought by rival Merck Sharpe & Dohme.
Forum Finance director Vince Tesoriero has lost a battle to stop receivers from selling luxury properties in which he and Bill Papas hold a stake pending the outcome of Westpac’s fraud case against him.
Lander & Rogers has recruited four leading corporate lawyers from KPMG Law, including highly-regarded partner David Morris, as part of the law firm’s aggressive growth strategy.
Macpherson Kelley is headed for trial next week in a case that alleges the law firm bungled the execution of a 10-year lease agreement with Shell for a service station in Melbourne, giving the energy giant an extra 320 square metres equating to $2.5 million in lost rent for its landlord client.
IP Australia has quashed an extension for a patent covering a Bayer oral contraceptive, saying the extension should have been calculated based on a drug that was included on the Australian Register of Therapeutic Goods at an earlier date.